COMPANY:

Tempus

"Tempus...today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and development in oncology....Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology."

"Tempus...announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc...to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests will be used to help discover and further validate biomarker profiles in patients who may benefit from treatment with elraglusib, a selective GSK-3β inhibitor."

"Tempus...announced a prospective study (NCT05257551), in collaboration with AstraZeneca...that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is currently open for enrollment."

"Fight Colorectal Cancer (Fight CRC) announced today that they have committed $150,000 per year for a three-year research fellowship to study clinical data at Tempus, a leader in artificial intelligence and precision medicine. The awarded researcher will receive access to Tempus de-identified datasets and analytical platform to identify insights and gaps that are occurring in colorectal cancer (CRC) clinical research...Part of the fellowship involves furthering biomarker testing, which has become an indispensable step in treatment planning for colon and rectal cancer patients. The patients’ treatment possibilities have been greatly extended due to the advancements in biomarker testing, although more research is needed to better understand biomarkers."

"Tempus...announced Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes a number of medical centers that are leveraging the program to advance its research, including Allegheny Health Network, Baylor College of Medicine, Rush University Medical Center, Stanford Cancer Center, TriHealth, UCLA Jonsson Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, and University of North Carolina Lineberger Comprehensive Cancer Center."

"GSK plc...and Tempus...have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data...The new collaboration builds from the existing relationship between the companies that began in 2020 on clinical trial enrolment of patients with certain types of cancer."

"Tempus...announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics...in support of its ongoing Phase II study of navtemadlin (KRT-232). Tempus’ CDx test, which will be developed on Tempus’ xT platform, will be used to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible for treatment with navtemadlin. Navtemadlin is a potent, selective, orally available MDM2 inhibitor that overcomes MDM2 dysregulation by restoring p53 activity and inducing apoptosis of TP53WT tumor cells."

"Tempus...announced a collaboration with the Children’s Oncology Group (COG)...to assist with their Pediatric MATCH Screening Trial APEC1621SC (NCT03155620). The Pediatric MATCH Screening Trial is studying the effectiveness of genetic testing-directed treatment in pediatric patients with solid tumors, non-Hodgkin lymphomas, and histiocytic disorders...Through this collaboration, Tempus will provide genomic sequencing for up to 300 eligible patients per year between 12 months and 21-years-old with recurrent or refractory solid tumors. Treating physicians have access to Tempus’ xT assay to help determine if a patient is a likely match for the Pediatric MATCH Screening Trial."

"Tempus...announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations."

"Tempus...announced a collaboration with Intermountain Healthcare...which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients...Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate whole transcriptomic data on existing samples for research purposes."

"Tempus...announced a new collaboration sponsored by Eli Lilly and Company designed to provide broader access to genomic testing to patients with advanced/metastatic non-small cell lung cancer (NSCLC)...Physicians will have the option of using the Tempus xT broad-panel genomic sequencing assay, designed to detect actionable alterations by sequencing tumor samples with matched normal saliva or blood samples, for their NSCLC patients."

"Tempus...announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). The test will originally be available on a limited basis alongside xF, Tempus’ 105-gene liquid biopsy assay, with a broader launch slated for later this year."

"Aadi Bioscience, Inc...announced partnerships with prominent next generation sequencing (NGS) providers and leaders in genomic testing and profiling, including Foundation Medicine, Tempus and others. We expect these collaborations to expedite patient identification for the ongoing PRECISION 1 trial of nab-sirolimus in patients harboring tumors with inactivating alterations in TSC1 or TSC2 genes....'We expect to report preliminary data from this trial in the first half of next year.'"

"Tempus...today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their patients with cancer."

"Pyramid Biosciences said Tuesday that it will join Tempus' TIME Trial Network for clinical trial patient identification under a new collaboration agreement between the two companies...The collaboration with Tempus, a company specializing in artificial intelligence for precision medicine, will support enrollment of patients for the trial...The collaboration with Tempus, a company specializing in artificial intelligence for precision medicine, will support enrollment of patients for the trial."

"Tempus...announced abstracts accepted for presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which convenes in New Orleans from April 8th until April 13th, 2022. The presented research demonstrates how Tempus’ comprehensive genomic sequencing capabilities generate high-quality DNA and RNA data, and empower clinicians to make informed, data-driven treatment decisions...Poster Title: 62/23 – Temporal concordance rates of pathogenic variants in liquid biopsies taken after solid tissue NGS profiling in a real-world pan-cancer cohort...Poster Title: 766/22 – Genomic and transcriptomic comparison between breast cancer patients of African and European ancestries demonstrates potential for biomarker-informed therapies."

"Tempus...announced the acquisition of Highline Sciences, a ​​specialized, full-service clinical contract research organization (CRO) focused on oncology...Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will help support and grow new and established business lines within Tempus, allowing the company to vertically integrate more clinical trial services when appropriate to complement its existing CRO partnerships."

"Tempus...today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10. The presented findings highlight the unique insights that Tempus’ data and smart diagnostics generate to advance breast cancer research."

"The expanded scope is anchored in new AI-based work, in which Tempus will collaborate with a multidisciplinary team of data scientists at Janssen to enhance the discovery and development of therapies for oncology indications using AI/ML and real-world evidence (RWE). This agreement leverages Tempus’ platform, including its multimodal data library, genomic sequencing offerings, and TIME Trial Network of clinical sites to advance the recruitment of patients."

"Tempus...announced that it will incorporate data from both the Memorial Sloan Kettering Cancer Center (MSK) OncoKB database and National Comprehensive Cancer Network® (NCCN®)’s Clinical Practice Guidelines in Oncology (NCCN Guidelines®) into its clinical reports. Tempus is collaborating with two of the world’s largest clinical decision-support resources to support the genomic foundational science and clinical applications of its xT assay...Tempus reports will reflect therapy choices based on molecular profile and corresponding NCCN Guidelines® recommendations and information from the OncoKB database, therefore making it easier for physicians to optimize treatment plans for their patients."

"Kronos Bio, Inc...and Tempus...today announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics tools...Under the agreement, Kronos Bio will have access to a number of precision medicine tools, including Tempus’ modeling lab, which houses a growing repository of molecularly profiled organoids. Access to such data and tools will help Kronos Bio accelerate the preclinical and clinical development of its current and future portfolio, by for example, using organoid models to generate biomarker hypotheses that can be tested in the clinic or in virtual molecularly defined patient cohorts drawn from Tempus’ extensive data sets...Kronos Bio also has the option to join Tempus’ TIME Trial® Network, which supports rapid patient identification, site activation and enrollment of select clinical trials."

"Tempus...announced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. The test assesses for relevant mutations in the DPYD (dihydropyrimidine dehydrogenase) gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies, aiming to avoid adverse effects. Like other algorithmic tests offered by Tempus, such as the Homologous Recombination Deficiency (HRD) and Tumor Origin (TO) tests, DPYD is available as an add-on option for physicians ordering Tempus’ xT solid tumor broad-panel assay, streamlining the ordering process and providing a comprehensive patient profile in the report."

"Tempus...announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration....Tempus is seeking approval for its xT-Onco assay, a broad-panel next-generation sequencing-based, in vitro diagnostic device. The submission includes companion diagnostic claims, tumor profiling claims, and microsatellite instability status, using DNA isolated from formalin-fixed paraffin embedded tumor tissue specimens, and matched normal specimens."

"Tempus...announced its new, state-of-the-art genomic sequencing lab in Durham’s Research Triangle Park (RTP)...RTP’s proximity to three tier-1 research universities has made it a hub for innovation, attracting some of the country’s most forward-thinking companies and making it the ideal location for Tempus’ new lab. When it opens in late 2021, Tempus aims to initially hire around 200 team members to staff the high-throughput lab, which will primarily focus on Tempus’ next-generation, genomic sequencing work in oncology. The lab will run the company’s leading, broad-panel solid and liquid assays, among others, which generate high-quality somatic and germline molecular data, along with therapeutic context. These findings help empower physicians to make personalized, data-driven decisions regarding their patients’ treatment options."

"Tempus...announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform. The study demonstrates how the platform has the potential to accelerate the application of patient derived biological models (organoids) in precision oncology and targeted therapeutic profiling programs through its use of molecular data and AI-based neural network development. Given the scale of Tempus’ organoid program, it now houses one of the largest repositories of these models in the world...The study, published in Cell Reports, analyzed Tempus’ platform of over 1,000 tumor organoid cultures, from patients whose tumors represent the most common subtypes of carcinoma in North America, to evaluate clinical and molecular determinants of organoid culture success, minimal growth factor dependencies by tissue of origin, and molecular concordance between organoids and source tumors."

"Tempus...announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity and specificity for calling SNVs, indels, CNVs, and gene rearrangements, making the liquid biopsy next-generation sequencing assay a preferred sequencing option should tumor tissue not be available...npj Precision Oncology published xF’s analytical validation, highlighting the assay’s high sensitivity and specificity for detecting single-nucleotide variants, insertions/deletions, copy number variants, and gene rearrangements."

"Tempus...announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 - 8....'By combining extensive tumor and germline genomic profiling with just-in-time clinical trial matching in our TIME Trial Network, Tempus is bringing the right treatments to patients facing cancer in a data-driven and expedited way'...Tempus’ cloud-based data and analytics platform for drug discovery and development, the de-identified records of 79,004 patients diagnosed with various cancer types who underwent Tempus xT and xF next generation sequencing were analyzed to study the association between KRAS variants and cancer subtypes."

"Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will convene virtually on April 10-15 and May 17-21...Tempus will present eight posters; including two in collaboration with outside investigators from Baylor College of Medicine, Harris Health Ben Taub Hospital, and the Dan L Duncan Comprehensive Cancer Center."

"Community Health Network announced today it is collaborating with Tempus...to improve patient health and outcomes through genomic testing. Among a variety of precision medicine solutions, Tempus offers a suite of oncology-focused genomic testing and targeted clinical trial matching. The platform analyzes clinical and molecular data points, connecting physicians with real-time treatment options and insights for patients based on their unique molecular profile."

"Tempus...today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samples related to patients enrolled in the dose escalation stage of the study, with the potential to use the same assay to sequence patients prospectively in the expansion stage of the clinical trial."

"Zentalis Pharmaceuticals...announced a strategic collaboration with Tempus to leverage the company’s patient-derived organoid biological modeling platform to strengthen Zentalis’ discovery and research capabilities....In harnessing Tempus’ cutting-edge approach, the collaboration will initially aim to validate Zentalis’ WEE1 inhibitor, ZN-c3, and its DNA damage response pathway in genetically distinct patient populations."

"Tempus...today announced the launch of its new germline sequencing assay, xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer. Tempus xG, which is now available to order, is performed by GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company...xG is designed for oncologists seeking to assess their patients’ hereditary risk of cancer by reporting clinically actionable, germline variants in genes such as BRCA1/2 and the Lynch syndrome genes. Through the collaboration with GeneDx, Tempus now offers an additional panel that assesses 52 common hereditary cancer genes and variants associated with increased cancer risks."

"The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of NeoGenomics, Inc…and Tempus to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer."

"Tempus...today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standard terms and custom data models to inform emerging research decisions...As part of the expanded agreement, Bristol Myers Squibb, a leading global biopharmaceutical company, has licensed additional data cohorts across multiple tumor types, with access to terabytes of new data. Each company is focused on identifying better ways to treat patients with unmet needs through the analysis of multi-modal data including whole-transcriptome sequencing data."

"Tempus…today unveiled a breakthrough technology for oncologists, Tempus ONE. This smart, voice-enabled, portable device brings Tempus’ proprietary platform and unparalleled library of multi-modal data to life, offering physicians real-time access to all the clinical insights and data contained in Tempus’ genomic reports in the palm of their hand. In beta today and launching more broadly in 2021, Tempus ONE is the first step toward bringing the full power of artificial intelligence to the point-of-care…Tempus has designed ONE as a portable device with the ability to relay all of the information contained in its reports, along with vast amounts of relevant additional data regarding that patient, in real-time, seamlessly integrating into their existing workflow."

"Tempus…today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the development of further CDx tests for A2’s other clinical development programs, which is part of its innovative approach to accelerate drug development…A2…is collaborating with Tempus to validate its leading xT sequencing assay to specifically identify patients with the LOH genetic alteration. This new diagnostic test is part of A2’s initiative to use its next-generation cell therapy TmodTM platform to revolutionize the treatment of solid tumor cancers, engineering T cells that target the loss of genetic material in tumors and enable the selective killing of tumor cells while leaving normal cells unharmed."

"Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Tempus xT broad-panel genomic sequencing assay, for a subset of patients with metastatic colorectal cancer (mCRC), as well as those with radioactive iodine refractory differentiated metastatic thyroid carcinoma (RAIR thyroid cancers). Looking ahead, Bayer and Tempus will continue to implement data-enriched initiatives dedicated to supporting patients."